Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes: 5-Year follow-up of the Hoorn study

Circulation

Volumn 101, Issue 13, 2000, Pages 1506-1511

  Hoogeveen, Ellen K ^a   Kostense, Pieter J ^b   Jakobs, Cornelis ^c   Dekker, Jacqueline M ^a   Nijpels, Giel ^a   Heine, Robert J ^c   Bouter, Lex M ^a   Stehouwer, Coen D A ^c  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cardiovascular diseases; Diabetes mellitus; Epidemiology; Mortality

Indexed keywords

HEMOGLOBIN A1C; HOMOCYSTEINE; SERUM ALBUMIN;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; MALE; MORTALITY; NETHERLANDS; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PRIORITY JOURNAL;

EID: 0034603841     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.101.13.1506     Document Type: Article

References (46)

1. Tunstall-Pedoe H, Woodward M, Tavendale R, A'Brooke R, McCluskey MK. Comparison of the prediction by 27 different factors of coronary heart disease and death in men and women of the Scottish heart health study: cohort study. BMJ. 1997;315:722-729.
2. Eastman RC, Keen H. The impact of cardiovascular disease on people with diabetes: the potential for prevention. Lancet. 1997;350(suppl I):29-32.
3. Balkau B, Pyörälä M, Shipley M, Forhan A, Jarrett J, Eschwège E, Pyörälä K. Non-cardiovascular disease mortality and diabetes mellitus. Lancet. 1997;350:1680. Letter.
4. Stengård JH, Tuomilehto J, Pekkanen J, Kivinen P, Kaarsalo E, Nissinen A, Karvonen MJ. Diabetes mellitus, impaired glucose tolerance and mortality among elderly men: the Finnish cohorts of the Seven Countries Study. Diabetologia. 1992;35:760-765.
5. Panzram G. Mortality and survival in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1987;30:123-131.
6. Ueland PM, Refsum H, Brattström L. Plasma homocysteine and cardiovascular disease. In: Francis RB Jr, ed. Atherosclerotic Cardiovascular Disease, Hemostasis, and Endothelial Function. New York, NY: Marcel Dekker Inc; 1992:183-236.
7. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA. 1995;274:1049-1057.
8. Mayer EL, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol. 1996;27:517-527.
9. Stehouwer CDA, Gall M-A, Hougaard P, Jakobs C, Parving H-H. Plasma homocysteine concentration predicts mortality in non-insulin-dependent diabetic patients with and without albuminuria. Kidney Int. 1999;55: 308-314.
10. Lussier-Cacan S, Xhignesse M, Piolot A, Selhub J, Davignon J, Genest J. Plasma total homocysteine in healthy subjects: sex-specific relation with biological traits. Am J Clin Nutr. 1996;64:587-593.
11. Nygård O, Vollset SE, Refsum H, Stensvold I, Tverdal A, Nordrehaug JE, Ueland PM, Kvåle G. Total plasma homocysteine and cardiovascular risk profile: the Hordaland Homocysteine Study. JAMA. 1995;274: 1526-1533.
12. Selhub J, Jacques PF, Wilson PWF, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA. 1993;270:2693-2698.
13. Hoogeveen EK, Kostense PJ, Beks PJ, Mackaay AJC, Jakobs C, Bouter LM, Heine RJ, Stehouwer CDA. Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus: a population-based study. Arterioscler Thromb Vasc Biol. 1998;18:133-138.
14. Welch GN, Loscalzo J. Mechanisms of disease: homocysteine and atherothrombosis. N Engl J Med. 1998;338:1042-1050.
15. Homocysteine Lowering Trialists' Collaboration. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. BMJ. 1998;316:894-898.
16. Beks PJ, Mackaay AJC, de Neeling JND, de Vries H, Bouter LM, Heine RJ. Peripheral arterial disease in relation to glycaemic level in an elderly Caucasian population: the Hoorn Study. Diabetologia. 1995;38:86-96.
17. World Health Organisation Study Group on Diabetes Mellitus. Technical Report Series No. 727. Geneva, Switzerland: World Health Organization; 1985.
18. WHO. International Classification of Diseases: Manual of the International Statistical Classification of Diseases, Injuries, and Causes of Death. Geneva, Switzerland: World Health Organization; 1977.
19. Ueland PM, Refsum H, Stabler SP, Malinow MR, Andersson A, Allen RH. Total homocysteine in plasma or serum: methods and clinical applications. Clin Chem. 1993;39:1764-1779.
20. Ubbink JB, Vermaak WJH, Bissbort S. Rapid high-performance liquid chromatographic assay for total homocysteine levels in human serum. J Chromatogr. 1991;565:441-446.
21. Corti M-C, Guralnik JM, Salive ME, Sorkin JD. Serum albumin level and physical disability as predictors of mortality in older persons. JAMA. 1994;272:1036-1042.
22. Pyörälä K, De Backer G, Graham I, Poole-Wilson P, Wood D, on behalf of the Task Force. Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Atherosclerosis. 1994;110:121-161.
23. Evans RW, Shaten J, Hempel JD, Cutler JA, Kuller LH, for the MRFIT Research group. Homocyst(e)ine and risk of cardiovascular disease in the multiple risk factor intervention trial. Arterioscler Thromb Vasc Biol. 1997;17:1947-1953.
24. Rall LC, Roubenoff R, Harris TB. Albumin as a marker of nutritional and health status. In: Rosenberg IH, ed. Nutritional Assessment of Elderly Populations. New York, NY: Raven Press; 1995:1-17.
25. Rothman KJ, Greenland S. In: Rothman KJ, Greenland S, eds. Modern Epidemiology. 2nd ed. Philadelphia, Pa: Lippincott-Raven; 1998: 115-134.
26. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D, Tishler PV, Hennekens CH. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA. 1992;268:877-881.
27. Verhoef P, Hennekens CH, Malinow MR, Kok FJ, Willett WC, Stampfer MJ. A prospective study of plasma homocyst(e)ine and risk of ischemic stroke. Stroke. 1994;25:1924-1930.
28. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet. 1995;346:1395-1398.
29. Arnesen E, Refsum H, Bønaa KH, Ueland PM, Førde OH, Nordrehaug JE. Serum total homocysteine and coronary heart disease. Int J Epidemiol. 1995;24:704-709.
30. Petri M, Roubenoff R, Dallal GE, Nadeau MR, Selhub J, Rosenberg IH. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet. 1996;348:1120-1124.
31. Nygård O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 1997;337:230-236.
32. Moustapha A, Naso A, Nahlawi M, Gupta A, Arheart KL, Jacobson DW, Robinson K, Dennis VW. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation. 1998;97:138-141.
33. Bostom AG, Silbershatz H, Rosenberg IH, Selhub J, D'Agostino RB, Wolf PA, Jacques PF, Wilson PWF. Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women. Arch Intern Med. 1999;159: 1077-1080.
34. Kark JD, Selhub J, Bostom A, Adler B, Rosenberg IH. Plasma homocysteine and all-cause mortality in diabetes. Lancet. 1999;353: 1936-1937. Letter.
35. van Beynum IM, Smeitink JAM, den Heijer M, te Poele Pothoff MTWB, Blom HJ. Hyperhomocysteinemia: a risk factor for ischemic stroke in children. Circulation. 1999;99:2070-2072.
36. Folsom AR, Nieto FJ, McGovern PG, Tsai MY, Malinow MR, Eckfeldt JH, Hess DL, Davis CE. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: the atherosclerosis risk in communities (ARIC) study. Circulation. 1998;98:204-210.
37. Alfthan G, Pekkanen J, Jauhiainen M, Pitkäniemi J, Karvonen M, Tuomilehto J, Salonen JT, Ehnholm C. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis. 1994; 106:9-19.
38. 6 and risk of myocardial infarction in US Physicians. J Am Coll Nutr. 1996;15:136-143.
39. Hoogeveen EK, Kostense PJ, Jager A, Heine RJ, Jakobs C, Bouter LM, Donker AJM, Stehouwer CDA. Serum homocysteine level and protein intake are related to risk of microalbuminuria: the Hoorn Study. Kidney Int 1998;54:203-209.
40. Bellamy MF, McDowell IFW, Ramsey MW, Brownlee M, Bones C, Newcombe RG, Lewis MJ. Hyperhomocysteinemia after an oral methionine load acutely impairs endothelial function in healthy adults. Circulation. 1998;98:1848-1852.
41. Chambers JC, McGregor A, Jean-Marie J, Obeid OA, Kooner JS. Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia: an effect reversible with vitamin C therapy. Circulation. 1999;99:1156-1160.
42. Nourooz-Zadeh J, Tajaddini-Sarmadi J, McCarthy S, Betteridge DJ, Wolff SP. Elevated levels of authentic plasma hydroperoxides in NIDDM. Diabetes. 1995;44:1054-1058.
43. Hoogeveen EK, Kostense PJ, Jakobs C, Bouter LM, Heine RJ, Stehouwer CDA. Does metformin increase the serum total homocysteine level in non-insulin-dependent diabetes mellitus? J Intern Med. 1997;242: 389-394.
44. Mooradian AD, Failla M, Hoogwerf B, Maryniuk M, Wylie-Rosett J. Selected vitamins and minerals in diabetes. Diabetes Care. 1994;17: 464-479.
45. Wollesen F, Brattström L, Refsum H, Ueland PM, Berglund L, Berne C. Plasma total homocysteine and cysteine in relation to glomerular filtration rate in diabetes mellitus. Kidney Int. 1999;55:1028-1035.
46. Kuller LH, Evans RW. Homocysteine, vitamins, and cardiovascular disease. Circulation. 1998;98:196-199. Editorial.